The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients - Full Text View

Purpose

The goal of this research is to see if pancreatic polypeptide (PP), a hormone that is naturally produced by the pancreas and that works to control the amount of glucose that the liver makes, will reduce the amount of insulin required for people who must take insulin to maintain their normal blood glucose level.

Condition	Intervention	Phase
Diabetes Mellitus, Type 1	Drug: Placebo Drug: Pancreatic Polypeptide (PP)	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment
Official Title:	The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 (Auto-immune) and Post-pancreatectomy Diabetic Patients

Resource links provided by NLM:

Genetics Home Reference related topics: type 1 diabetes

Drug Information available for: Insulin

U.S. FDA Resources

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:

Total Amount of Insulin Administered While on Placebo/PP. [ Time Frame: 2 years ]
Glucose values and the pattern of glycemic excursions over the 72 hour test period.

Secondary Outcome Measures:

Frequency of Hypoglycemia Defined as < 60 mg/dl. [ Time Frame: 72 hours ]


Enrollment:	8
Actual Study Start Date:	October 2007
Study Completion Date:	June 2010
Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Saline Placebo Saline	Drug: Placebo 2pmol/kg-1/min-1 placebo infused continuously over 72 hours. Other Name: Saline
Active Comparator: Pancreatic Polypeptide Pancreatic Polypeptide	Drug: Pancreatic Polypeptide (PP) 2pmol/kg-1/min-1 PP infused continuously over 72 hours. Other Name: PP

Detailed Description:

The pancreas is a large gland located behind the stomach. One of the functions of the pancreas is to produce two hormones: insulin and pancreatic polypeptide. Insulin helps the cells to take in glucose. The liver makes glucose and insulin normally acts to decrease or shut off the liver's production of glucose. However, in patients whose pancreas no longer makes insulin or makes low levels of pancreatic polypeptide the liver cannot perform these duties as well. Studies have shown that these important functions of the liver are improved for these patients when pancreatic polypeptide is given together with their insulin. Because PP increases the liver's sensitivity to insulin and thereby reduces the amount of glucose produced by the liver, this will result in fewer swings in blood sugar levels both in the upper and lower range. With fewer swings in blood glucose, a patient should decrease the amount of insulin used. One of the main benefits of lowering total insulin requirement is a reduction in the development of dangerous low blood sugar levels.

Eligibility


Ages Eligible for Study:	18 Years to 75 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male and female volunteers between the ages of 18-75 with:
10 subjects who are status post pancreatic resection and 10 volunteers who are Type 1 diabetic for > 8 years (volunteers must have a stable glycemic profile that includes use of an insulin pump to control their blood glucose) with or without prior pancreatic resection.
HbA1c levels ≤ 8.5.

Exclusion Criteria:

Lactating or pregnant females.
Brittle or Labile diabetics: Volunteers with extremely erratic patterns of glucose control with large fluctuations in glucose levels for no obvious reason.
Allergy to beef or beef by-products.
Hypoglycemia within the past year requiring medical or other assistance to correct.
Known autonomic neuropathy.
Documented blood glucose under 60 mg within the past year and hypoglycemic unawareness.
Durations of type 1 Diabetes Melitis (DM) ≤ 8 years.
Not currently on pump therapy.
Type 1 DM who has a BMI ≥ 35.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00791076

Locations


United States, Maryland
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224

Sponsors and Collaborators

Johns Hopkins University

Investigators


Principal Investigator:	Dariush Elahi, PhD	Johns Hopkins University

More Information


Responsible Party:	Johns Hopkins University
ClinicalTrials.gov Identifier:	NCT00791076 History of Changes
Other Study ID Numbers:	NA_00010957
Study First Received:	November 13, 2008
Results First Received:	May 1, 2017
Last Updated:	June 29, 2017

Keywords provided by Johns Hopkins University:


Insulin pump therapy Type 1 diabetic Chronic pancreatitis Pancreatic resection Pancreatic polypeptide

Additional relevant MeSH terms:


Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases	Insulin Pancreatic Polypeptide Hypoglycemic Agents Physiological Effects of Drugs Gastrointestinal Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on August 18, 2017